Found 61 articles
NanoViricides, Inc. Has Filed its Annual Report: Strengthened Financial Position and Rapidly Developing Novel Coronavirus Drug Program
NanoViricides, Inc., reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2020 with the Securities and Exchange Commission on Tuesday, October 12, 2020.
Nuvation Bio Announces FDA Acceptance of Investigational New Drug (IND) Application for NUV-422 for Treatment of Patients with High-grade Gliomas
--First compound from pipeline of six early-stage oncology programs to advance into clinical development-- --Company anticipates initiating Phase 1/2 clinical trial of NUV-422 by Q1 2021-- [13-October-2020] NEW YORK , Oct. 13, 2020 /PRNewswire/ -- Nuvation Bio, Inc. , an oncology company focused on revolutionizing cancer treatment by discovering, developing
Clinical-stage biopharmaceutical firm ESCAPE Bio has snagged a $73 million crossover financing deal, led by Wellington Management Company, which will help advance the company’s two clinical development programs of precision neurology medicines for patients with genetic neurodegeneration.
ESCAPE Bio Closes $73 Million in Crossover Financing to Advance Clinical Development of Precision Neurology Medicines for Genetic Neurodegeneration
ESCAPE Bio, a clinical stage company developing novel, precisely targeted therapeutics for genetic neurodegenerative diseases, today announced the closing of a $73M financing led by Wellington Management Company LLP. Additional new investors include Avidity Partners, CAM Capital, New Leaf Ventures, Rock Springs Capital, Surveyor Capital (a Citadel company) and Sphera Funds Management, who join existing inves
Adagio Therapeutics Strengthens Management Team with Appointments of Eric Kimble as Chief Commercial Officer and Ed Campanaro as SVP of Clinical Operations
Adagio Therapeutics, Inc., a company focused on the development of best-in-class antibodies to provide broad protection against SARS-CoV-2, SARS-CoV-1 and additional circulating bat coronaviruses, announced it has strengthened its management team with the addition of Eric Kimble as Chief Commercial Officer and Ed Campanaro as Senior Vice President of Clinical Operations.
Mereo BioPharma Strengthens Management Team; Appoints John Lewicki, PhD, as Chief Scientific Officer and Ann Kapoun, PhD, as SVP of Translational Research and Development
Mereo BioPharma Group plc, “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announced the appointments of John Lewicki, PhD, as Chief Scientific Officer, and Ann Kapoun, PhD, as Senior Vice President of Translational Research and Development.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 12, 2020.
Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the appointment of Julie Anne Smith to its Board of Directors. Ms. Smith has also been appointed to the Compensation Committee of the Boa
AbVision, Inc., an innovative biopharmaceutical company, announced today that the Company has developed a biosuperior anti-CD47 therapeutic antibody (AVI-105), powered by its SpeedyAb™ technology platform of therapeutic antibody.
OliX Pharmaceuticals Presents at BIO KOREA 2020 International ConventionDong-Ki Lee, Ph.D., founder and Chief Executive Officer discussed the application of company’s novel RNAi therapy platform in treatment of COVID-19
OliX Pharmaceuticals , Inc. (KOSDAQ: 226950), a key player in the development of RNAi therapeutics, today announced that Dong-Ki Lee, Ph.D., founder and Chief Executive Officer presented the Company’s platform technology and discussed the potential utility of siRNA therapeutics in combatting COVID-19 at BIO KOREA 2020 . During his session, “RNAi therapeutics against COVID-19,” Dr. Lee shared strategies to develop COVID-19 viru
5/18/2020Clinical trial updates not related to COVID-19 are on the upswing, partly because some companies are announcing trial information ahead of the upcoming American Society of Clinical Oncology virtual meeting being held at the end of the month. Here’s a look.
Vir Biotechnology, Inc., a clinical-stage immunology company focused on treating and preventing serious infectious diseases, provided a corporate update and reported financial results for the first quarter ended March 31, 2020.
ESCAPE Bio, Inc., a precision neurology company, today announced that Julie Anne Smith, Chief Executive Officer, will present at the Bank of America Securities Virtual Health Care Conference on Thursday, May 14th at 1:40 p.m. Eastern Time.
ESCAPE Bio, Inc. , today announced Paul Wren, Ph.D., has been appointed as Chief Scientific Officer.
2/24/2020Mid-February had a solid number of clinical trial announcements. Here’s a look.
ESCAPE Bio, Inc., a clinical stage company developing novel, precisely targeted therapeutics for genetically defined neurodegenerative diseases, today announced that Julie Anne Smith, Chief Executive Officer, will present at the Cowen 40th Annual Health Care Conference on Tuesday, March 3, 2020.
Feb. 19, 2020 13:00 UTC ESCAPE Bio to Present at the 9 th Annual SVB Leerink Global Healthcare Conference SAN FRANCISCO--( BUSINESS WIRE )-- ESCAPE Bio, Inc. , a clinical stage company developing novel, precisely targeted therapeutics for genetically defined neurodegenerative diseases, today announced that Julie Anne Smith, Chief Executive Officer, will present at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2020. Presentation details
Feb. 6, 2020 14:30 UTC ROYAL OAK, Mich.--( BUSINESS WIRE )-- Immunis.AI, a privately held immunogenomics company with a patented liquid biopsy platform, today announced that its President and Chief Executive Officer, Mark McDonough, will present at the BIO CEO & Investor Conference being held in New York City from February 10-11, 2020. Date: Tuesday, February 11 th Time: 10:00 AM Track: Diagnostics Venue: Ziegfeld Room, New York Marriott Marquis
Caladrius Biosciences, Inc., a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced that David J. Mazzo, PhD, President and Chief Executive Officer of the Caladrius, will present a company overview at the following conferences in February:.
ESCAPE Bio, Inc., a clinical stage company developing novel, precisely targeted therapeutics for genetically defined neurodegenerative diseases, announced that Julie Anne Smith, Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020.